Rationale: The predominant cause of chronic lung allograft failure is small airway obstruction arising from bronchiolitis obliterans. However, clinical methodologies for evaluating presence and degree of small airway disease are lacking.
Objectives: To determine if parametric response mapping (PRM), a novel computed tomography voxel-wise methodology, can offer insight into chronic allograft failure phenotypes and provide prognostic information following spirometric decline.
Methods: PRM-based computed tomography metrics quantifying functional small airways disease (PRM fSAD ) and parenchymal disease (PRM PD ) were compared between bilateral lung transplant recipients with irreversible spirometric decline and control subjects matched by time post-transplant (n = 22). PRM fSAD at spirometric decline was evaluated as a prognostic marker for mortality in a cohort study via multivariable restricted mean models (n = 52).
Measurements and Main Results:
Patients presenting with an isolated decline in FEV 1 (FEV 1 First) had significantly higher PRM fSAD than control subjects (28% vs. 15%; P = 0.005), whereas patients with concurrent decline in FEV 1 and FVC had significantly higher PRM PD than control subjects (39% vs. 20%; P = 0.02). Over 8.3 years of follow-up, FEV 1 First patients with PRM fSAD greater than or equal to 30% at spirometric decline lived on average 2.6 years less than those with PRM fSAD less than 30% (P = 0.004). In this group, PRM fSAD greater than or equal to 30% was the strongest predictor of survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV 1% predicted (P = 0.04).
Conclusions: PRM is a novel imaging tool for lung transplant recipients presenting with spirometric decline. Quantifying underlying small airway obstruction via PRM fSAD helps further stratify the risk of death in patients with diverse spirometric decline patterns.
Keywords: bronchiolitis obliterans syndrome; chronic lung allograft dysfunction; parametric response mapping; computed tomography of the chest; prognosis Chronic allograft failure, the major cause of poor long-term survival in patients undergoing lung transplantation, presents predominantly as obstructive airflow limitation by spirometry, termed bronchiolitis obliterans syndrome (BOS). Functional small airways disease (fSAD) secondary to fibrotic obliteration or bronchiolitis obliterans (BO) is the primary driver of this clinical spirometric decline (1) . However, there is growing awareness that chronic lung allograft dysfunction is a heterogeneous disorder with pathologic processes including BO and interstitial or parenchymal fibrosis in varying combinations and severity within an individual (2) (3) (4) . Diverse physiologic decline patterns have been shown to provide prognostic information; isolated decline in FEV 1 as compared with concurrent FEV 1 and FVC fall on spirometry is associated with superior survival suggesting that patients with fSAD versus parenchymal disease have heterogeneous outcomes (5, 6) . In patients with BOS, the degree of airflow obstruction by spirometry is also linked to survival (7, 8) . Hence, a clinical methodology to quantitate fSAD and to differentiate underlying phenotypes would have significant impact on care of lung transplant recipients.
Small airways, the predominant histologic target of fibrotic remodeling in a chronically rejecting lung allograft, have been termed the "silent zone" of the lung secondary to difficulty in evaluating small airway pathology (9) . Transbronchial biopsies fail to adequately sample small airways and have limited sensitivity in diagnosing BO in lung transplant recipients (10, 11) . Similarly, routine radiographic imaging techniques cannot easily visualize small airways, although some direct and indirect signs of bronchiolar disease have been proposed on high-resolution computed tomography (HRCT) chest imaging. These findings, including air trapping and bronchiectasis, have limited sensitivity and specificity for a diagnosis of BOS and provide no prognostic information (12) (13) (14) .
Parametric response mapping (PRM) is a voxel-based methodology for image analysis that has been demonstrated to be effective in improving the diagnostic ability of radiographic methodologies, such as magnetic resonance imaging and CT scans in various organs and disease states (15) (16) (17) (18) (19) . In the lung, comparison of inspiratory and expiratory images on a voxel-by-voxel basis by image coregistration has been shown to provide a quantitative measure of fSAD in patients with chronic obstructive pulmonary disease (16, (20) (21) (22) . This unique ability to quantitate fSAD on CT chest images suggests that PRM can potentially be used as an imaging biomarker for evaluation of BO in lung allografts. In this study, we investigate the PRM signature of lung transplant recipients with spirometric decline and demonstrate the utility of this methodology to evaluate disease phenotype and survival.
Methods

Patient Population
Bilateral lung transplant recipients at the University of Michigan Health System between 1991 and 2014 were included in the study group. Many patients included in our previous analysis of spirometric function following lung transplantation (6) were also included in this study, now with a longer follow-up period. Patients were managed in line with a standard clinical algorithm (23) . Baseline FEV 1 was defined according to International Society for Heart and Lung Transplantation (ISHLT) guidelines as the average of the two highest FEV 1 values obtained greater than or equal to 3 weeks apart post-transplant (24) . FVC baseline was similarly defined as the average of the two highest FVC values obtained greater than or equal to 3 weeks apart post-transplant (6) . Persistent spirometric decline was defined as a decline in FEV 1 and/or FVC to less than 80% of the respective post-transplant baseline as measured by two consecutive FEV 1 and/or FVC values greater than or equal to 3 weeks apart. Patients were assigned to the two spirometric decline pattern groups, FEV 1 First or Concurrent, as previously described (6) . Briefly, FEV 1 First was defined as a persistent fall in FEV 1 with a preserved FVC at the time of spirometric decline. Concurrent decline pattern was defined as a fall in both FEV 1 and FVC to less than 80% of the respective post-transplant baselines on the same date (6) . A simple algorithm outlining the criteria for development of persistent spirometric decline and its various patterns is provided in Figure 1 . BOS grade was defined per ISHLT guidelines (25) . Time of death was assessed up to October 21, 2015 ; all other data were censored.
Computed Tomography
CT data were obtained as whole-lung volumetric CT scans at full inspiration (total lung capacity) and incremental scans at relaxed expiration (functional residual capacity) on General Electric 64-detector scanners (General Electric, Boston, MA) and reconstructed using a bone reconstruction kernel. Slice thicknesses were 1.25 mm for all scans, with incremental scans acquired
Step 1: Define baseline FEV 1 and FVC (average of 2 highest FEV 1 or FVC values attained post-transplant)
Step 2:
Identify persistent spirometric decline: Either FEV 1 or FVC have fallen to < 80% of baseline value as measured by 2 spirometric values performed ≥ 3 weeks apart
Step 3: Categorize as FEV 1 PRM was applied to all paired CT scans and has been previously described (17) . Briefly, lungs from both paired CT scans were segmented from the thoracic cavity using an in-house algorithm written in Matlab (The MathWorks, Inc., Natick, MA). The whole-lung inspiratory CT scan was spatially aligned to the incremental expiratory CT scan using Elastix, an open source image registration algorithm (27, 28) . This process allows the paired images to share the same geometric space, where each voxel, the smallest unit of volume in a three-dimensional image dataset, consists of HU values at inspiration and expiration. Each voxel was classified based on a scheme of three predetermined thresholds as previously described (17) . In brief, voxels with values greater than or equal to 950 HU and less than 2810 HU at inspiration and greater than or equal to 2856 HU at expiration were classified normal (PRM Normal , green voxels), greater than or equal to 950 HU and less than 2810 HU at inspiration and less than 2856 at expiration were functional small airways disease (PRM fSAD , yellow voxels), and greater than or equal to 2810 HU at inspiration were parenchymal disease (PRM PD , purple voxels). The relative lung volumes, calculated as the sum of all voxels within a class normalized to the sum of all voxels within the expiratory lungs multiplied by 100, were used as global measures.
Statistical Analysis
Statistical analyses were performed using R version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). In the casecontrol analysis, continuous variables were compared using linear mixed models with a random effect for matched pair (29) , which corresponds to a matched pair Student's t test when case/control status is the only predictor in the model. Logistic and multinomial random effects models, with a random effect for matched pair (30) , were used to compare binary and categorical predictors between matched cases and control subjects. For matched pair comparisons of PRM values, Wilcoxon signed rank tests were done (31) . Multivariable linear mixed models (29) , stratified by spirometric decline group of the case and including a random effect for matched pair, were used to describe associations between PRM values and case status adjusted for age, baseline FEV 1% predicted, and baseline FVC % predicted.
Demographics of the retrospectively followed lung transplant recipients with persistent FEV 1 decline are reported as mean 6 SD for continuous predictors or count (percent) for categorical predictors, stratified by availability of PRM data. Demographic differences between patients with versus without available PRM data were compared using chi-square (32) or Fisher exact (33) tests for categorical descriptors, as appropriate, or two-sample Student's t tests for continuous descriptors (34) . Associations between clinical risk factors for BOS occurring before spirometric decline and PRM fSAD values at spirometric decline (> or ,30%), adjusted for time to spirometric decline, were assessed using negative binomial regression for count-oriented outcomes or logistic regression for binary outcomes (35) . Survival curves were estimated using the Kaplan-Meier method (36) with twosample comparisons conducted using both restricted mean (RM) tests (37) and logrank tests (38) (39) (40) . Multivariable censored survival regression analysis was conducted using the RM model framework (41) .
Results
Spirometric Decline Patterns Are Associated with Distinct PRM Signatures
We first investigated the application of PRM to patients with spirometric decline in a case-control fashion. Cases were defined as bilateral lung transplant recipients experiencing a persistent spirometric decline ( Figure 1 ) in the absence of obvious confounders in concordance with ISHLT guidelines (25) . Cases were restricted to patients with irreversible lung function decline as defined by no improvement in FEV 1 to greater than or equal to 80% of the post-transplant baseline during the entire study period (n = 22). Control subjects (CT scans obtained from patients with stable pulmonary function) were matched to cases by time from transplantation to CT scan. Table 1 . FEV 1 First patients were younger than their respective control subjects (39 6 18 yr vs. 50 6 9 yr; P = 0.04) and had a lower baseline FVC % predicted post-transplant (82 6 14% vs. 93 6 12%; P = 0.03). Concurrent group patients were not significantly different from their matched control subjects.
Quantification of fSAD (PRM fSAD , yellow) and parenchymal disease (PRM PD , purple) obtained by PRM was compared between spirometric decline groups and their respective control subjects (Figure 2 In a model that controlled for age, baseline FEV 1% predicted, and baseline FVC % predicted, FEV 1 First patients continued to have significantly more PRM fSAD than their respective control group (30% vs. 18%; P = 0.03) ( Table 2) .
Similarly, Concurrent patients had significantly more PRM PD than their respective control subjects after adjusting for these variables (34% vs. 15%; P = 0.02) ( Table 3) . Representative cross-sectional HRCT images and associated PRM images from a control, FEV 1 First, and Concurrent patient, respectively, are shown in Figure 3 .
Quantitative Assessment of fSAD by PRM Predicts Survival in Patients with Spirometric Decline
To evaluate if PRM values at the onset of spirometric decline can provide prognostic information, a retrospective analysis of the prospective cohort of 287 bilateral lung transplant recipients at the University of Michigan from 1991 to 2014 was performed ( Figure 4 ). The study group included all patients with persistent spirometric decline who had a CT chest in the time range of 30 days before to 60 days after spirometric decline that was available for PRM analysis (n = 64). Demographics of patients with and without PRM data available were not significantly different (Table 4 ). The clinical information at the time of each patient's spirometric decline event was closely reviewed. Patients with confounding factors responsible for the spirometric decline event were removed from the cohort (n = 12). Confounding conditions included acute abdominal process (n = 1), acute rejection that eventually improved (n = 1), bronchial stenosis (n = 1), drug toxicity (n = 2), flare of connective tissue disease (n = 1), neuromuscular weakness (n = 2), organizing pneumonia (n = 1), and volume overload (n = 3). Thus, 52 patients comprised the final study group with persistent spirometric decline. Of those, 75% (39 of 52) had an FEV 1 First decline pattern, and 25% (13/52) had a Concurrent decline pattern.
The distributions of PRM fSAD and PRM PD obtained at the time of spirometric decline are shown in Figure 5 . fSAD greater than or equal to 30% had more episodes of acute rejection (average 1.77 vs. 0.9 episodes; P = 0.02) and were more likely to have a history of lymphocytic bronchitis (54% vs. 23%; P = 0.04) as compared with patients with low PRM fSAD (Table 5 ). There was no significant difference in history of bronchoalveolar lavage neutrophilia, history of Pseudomonas colonization or infection, history of Aspergillus fumigatus colonization or infection, history of cytomegalovirus pneumonitis, or history of community-acquired respiratory virus infection between patients with low versus high PRM fSAD . Kaplan-Meier survival curves based on spirometric decline group status and PRM fSAD values are shown in Figure 6 . PRM fSAD was found to be a significant predictor of survival in FEV 1 First patients (RM, P = 0.004; log-rank, P = 0.038). Over 8.3 years of follow-up, FEV 1 First patients with PRM fSAD greater than or equal to 30% (10 of 39 patients; 26%) at the time of spirometric decline lived an average of 2.50 years as compared with 5.12 years in patients with PRM fSAD less than 30% (average difference, 2.6 yr; 95% CI, 
0.83-4.41 yr)
. A multivariable analysis was performed using RM regression as shown in Table 6 . In a model adjusted for age, baseline FEV 1% predicted, baseline FVC % predicted, and BOS grade at spirometric decline, PRM fSAD greater than or equal to 30% in FEV 1 First patients was the only significant predictor of survival; those with PRM fSAD greater than or equal to 30% lived lifetimes that were 48% shorter over the follow-up period (95% CI, 23-97% shorter; P = 0.04)., PRM fSAD was also evaluated as a predictor of survival in Concurrent patients and subsequently in all patients regardless of spirometric decline pattern. Interestingly, even in Concurrent patients, PRM fSAD continued to be a significant predictor of survival (RM P = 0.005; log-rank, P = 0.029). Over 5.1 years of follow-up, Concurrent patients with PRM fSAD greater than or equal to 30% lived an average of only 0.27 years as compared with Concurrent patients with PRM fSAD less than 30% who lived an average of 2.31 years ( Figure 6B ; average difference 2.04 yr; 95% CI, 0.61-3.47 yr). All three patients in the Concurrent spirometric decline group with PRM fSAD greater than or equal to 30% died within 4 months of their spirometric decline (range, 82-119 d).
In the entire cohort including both FEV 1 First and Concurrent patients, those with PRM fSAD greater than or equal to 30% had a significantly shorter average survival following spirometric decline (RM, P = 0.001; log-rank, P = 0.018) ( Figure 6C Figure 8 outlines a useful clinical algorithm to predict survival following spirometric decline with the application of PRM data.
Discussion
In this study, we evaluate the application of PRM, a voxel-wise image analysis technique, in a lung transplant population to quantify small airway obstruction and offer prognostic information. We demonstrate that PRM-based evaluation of chest CT images provides a unique signature in patients with diverse spirometric decline patterns after lung transplantation. Patients who presented with isolated FEV 1 decline have significantly higher PRM fSAD than their control subjects matched by time post-transplant, whereas patients with Concurrent decline have higher PRM PD . Furthermore, we demonstrate that degree of fSAD as assessed by PRM is a robust predictor of survival with significantly poorer survival noted in patients with PRM fSAD values greater than or equal to 30% at the onset of spirometric decline. We have shown that PRM can offer unique rejection signatures and predict survival after onset of chronic rejection in lung transplant recipients.
This study is the first to demonstrate the utility of PRM as a prognostic measure in a lung transplant population with spirometric decline. We demonstrate that higher PRM fSAD at the time of spirometric decline onset predicts significantly worse survival. In the FEV 1 First cohort, patients with PRM fSAD greater than or equal to 30% 
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had an average survival of only 2.5 years compared with 5.12 years in patients with PRM fSAD less than 30%. Significant variability has been described in the rate of spirometric decline and survival in patients presenting with chronic allograft failure, underscoring the need to identify prognostic markers that can be used in guiding therapeutic interventions and in time consideration of retransplantation (8, 42, 43) . In patients with BOS, clinical factors, such as early versus late and rapid versus gradual onset, have been associated with abrupt decline and mortality (8, 43) . Similarly, spirometric variables, such as higher BOS grade at onset and progression to higher BOS grades, have been shown to portend a poor prognosis (7, 8) . PRM fSAD represents the first quantitative radiographic measure of small airway obstruction, which has been demonstrated to correlate with survival in lung allograft recipients presenting with spirometric decline. In a recent investigation, PRM fSAD was shown to increase over time after BOS onset, thus further demonstrating the correlation of this measure with disease severity (44) .
Illustrated in Figure 9 are representative HRCT images and PRM analyses from a patient before and after BOS onset demonstrating progressive increase in PRM fSAD values over time. It is also important to note that in patients with isolated FEV 1 decline pattern, PRM fSAD greater than or equal to 30% was found to be the only significant predictor of survival in a model adjusting for age, baseline FEV 1% predicted, baseline FVC % predicted, and BOS grade at spirometric decline. Thus PRM methodology offers a simple radiographic biomarker of disease severity with a predictive ability that is more robust than physiology alone. Furthermore, because chest CT scans are routinely performed in lung transplant recipients when spirometry declines to exclude causes of decline other than chronic rejection, PRM can have wide clinical applicability. A significant contribution of this study is that it provides a novel approach of combining physiologic and radiographic phenotyping for prognostication and with PRM fSAD greater than or equal to 30% have significantly shorter average survival than patients with PRM fSAD less than 30% (2.50 6 0.6 vs. 5.12 6 0.7 yr; restricted mean [RM], P = 0.004; log-rank, P = 0.038). (B) Concurrent patients (presenting with simultaneous decline in both FEV 1 and FVC) with PRM fSAD greater than or equal to 30% similarly had significantly shorter average survival than those with PRM fSAD less than 30% (0.27 6 0.03 vs. 2.31 6 0.7 yr; RM, P = 0.005; log-rank, P = 0.029). (C) PRM fSAD greater than or equal to 30% is a key prognostic indicator in all patients regardless of spirometric decline pattern (RM, P = 0.001; log-rank, P = 0.018). (2, 3, 5, 25) . These patients are generally described to have radiographic interstitial or alveolar changes and histologic evidence of parenchymal and pleural fibrosis (2, 3, 5) . It is important to note that PRM PD does not imply the presence of restrictive chronic lung allograft dysfunction with certainty; PRM PD reflects any process that results in hyperattenuation or increased parenchymal density, which could include infection, pulmonary edema, organizing pneumonia, and so forth. These various processes must be excluded before an elevated PRM PD can be attributed to restrictive chronic lung allograft dysfunction. It has also been postulated that the Concurrent group may also include patients with very severe obstruction leading to premature airway closure and a resultant drop in FVC (45); fibrotic airway narrowing and obstruction has been demonstrated in the lungs of patients with restrictive chronic lung allograft dysfunction (4) .
Interestingly, although patients with Concurrent spirometric decline typically have higher PRM PD , 23% (3 of 13) of the Concurrent patients in our larger cohort had PRM fSAD values greater than or equal to 30%, suggesting significant fSAD. Furthermore, in the Concurrent patients in our cohort, PRM fSAD greater than or equal to 30% predicted death within 4 months suggesting that even in patients with a Concurrent spirometric decline pattern, PRM fSAD may prove very useful to the clinician in identifying rejection phenotype. However, because of the small sample size in the Concurrent group, these findings must be confirmed in a larger cohort.
Our study is limited by its retrospective study design and evaluation of PRM at a single time point. However, the demonstration of utility of PRM in predicting prognosis and evaluating disease phenotype in lung transplant recipients provides the foundation for future prospective multicentric longitudinal studies to investigate use of this novel radiographic methodology in monitoring graft health in lung transplant recipients.
Assessment of the amount of fSAD present in a healthy lung transplant patient population with baseline graft function also requires further study. In a prior study evaluating the utility of PRM to quantify fSAD and aid in BOS diagnosis in a hematopoietic stem cell transplant population, nontransplanted healthy nonsmoking control subjects had an average PRM fSAD value of 8.4% (17) . In a cohort of current or previous smokers with normal FEV 1 fSAD values in a normal lung transplant cohort were noted to be higher than those expected for nontransplanted normal subjects (44) . Because a lung allograft is subjected to various insults unique to transplantation, such as ischemia reperfusion injury, immune insults, denervation, and lack of bronchial circulation, it is possible that perhaps a higher threshold for normal PRM fSAD will have to be considered in this population. A prospective analysis of serial PRM data over time in a transplant population would be better able to address this finding.
In summary, we have offered a view of the PRM landscape in a group of lung transplant recipients with persistent spirometric decline. We demonstrate that PRM, a quantitative imaging application, can offer insight into chronic lung allograft dysfunction phenotypes and provide prognostic information that has relevance in clinical care and future clinical trials. n ORIGINAL ARTICLE
